These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

370 related items for PubMed ID: 37475030

  • 1. Efficacy of transarterial therapy combined with first-line tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: a network meta-analysis.
    Hu L, Lin J, Shi X, Wang A.
    World J Surg Oncol; 2023 Jul 21; 21(1):208. PubMed ID: 37475030
    [Abstract] [Full Text] [Related]

  • 2. Efficacy of Transarterial Chemoembolization Combined with Molecular Targeted Agents for Unresectable Hepatocellular Carcinoma: A Network Meta-Analysis.
    Zhang Z, Wu Y, Zheng T, Chen X, Chen G, Chen H, Guo X, Zheng S, Xie X, Zhang B.
    Cancers (Basel); 2022 Jul 29; 14(15):. PubMed ID: 35954373
    [Abstract] [Full Text] [Related]

  • 3. Transarterial chemoembolization (TACE) plus tyrosine kinase inhibitors versus TACE in patients with hepatocellular carcinoma: a systematic review and meta-analysis.
    Duan R, Gong F, Wang Y, Huang C, Wu J, Hu L, Liu M, Qiu S, Lu L, Lin Y.
    World J Surg Oncol; 2023 Mar 31; 21(1):120. PubMed ID: 37004052
    [Abstract] [Full Text] [Related]

  • 4. Clinical Effectiveness and Safety of Transarterial Chemoembolization: Hepatic Artery Infusion Chemotherapy Plus Tyrosine Kinase Inhibitors With or Without Programmed Cell Death Protein-1 Inhibitors for Unresectable Hepatocellular Carcinoma-A Retrospective Study.
    Chen Y, Jia L, Li Y, Cui W, Wang J, Zhang C, Bian C, Wang Z, Lin D, Luo T.
    Ann Surg Oncol; 2024 Nov 31; 31(12):7860-7869. PubMed ID: 39090499
    [Abstract] [Full Text] [Related]

  • 5. Transarterial Chemoembolization Followed by Hepatic Arterial Infusion Chemotherapy Combined a Tyrosine Kinase Inhibitor for Treatment of Large Hepatocellular Carcinoma.
    Chen B, Dai H, Yang J, Zhang G, Wen C, Xiang X, Lin R, Huang Y.
    Curr Cancer Drug Targets; 2023 Nov 31; 23(7):564-571. PubMed ID: 36790005
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of first-line treatments for advanced hepatocellular carcinoma patients: a systematic review and network meta-analysis.
    Li J, Yang B, Teng Z, Liu Y, Li D, Qu X.
    Front Immunol; 2024 Nov 31; 15():1430196. PubMed ID: 39355238
    [Abstract] [Full Text] [Related]

  • 7. The Significance of Transarterial Chemo(Embolization) Combined With Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma in the Era of Systemic Therapy: A Systematic Review.
    Ke Q, Xin F, Fang H, Zeng Y, Wang L, Liu J.
    Front Immunol; 2022 Nov 31; 13():913464. PubMed ID: 35677059
    [Abstract] [Full Text] [Related]

  • 8. Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non-randomized study.
    He MK, Le Y, Li QJ, Yu ZS, Li SH, Wei W, Guo RP, Shi M.
    Chin J Cancer; 2017 Oct 23; 36(1):83. PubMed ID: 29061175
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of transarterial chemoembolization plus lenvatinib combined with PD-1 inhibitors versus transarterial chemoembolization plus lenvatinib for unresectable hepatocellular carcinoma: a meta-analysis.
    Chen Y, Jia L, Li Y, Cui W, Wang J, Zhang C, Bian C, Luo T.
    Front Immunol; 2024 Oct 23; 15():1466113. PubMed ID: 39281676
    [Abstract] [Full Text] [Related]

  • 10. Transarterial Chemoembolization Combined with Lenvatinib for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Pei X, Zhao J, Wang Z.
    Oncology; 2024 Oct 23; 102(8):688-702. PubMed ID: 38190815
    [Abstract] [Full Text] [Related]

  • 11. Hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors versus lenvatinib and PD-1 inhibitors for HCC refractory to TACE.
    Diao L, Wang C, You R, Leng B, Yu Z, Xu Q, Cheng Y, Yin G.
    J Gastroenterol Hepatol; 2024 Apr 23; 39(4):746-753. PubMed ID: 38240156
    [Abstract] [Full Text] [Related]

  • 12. Real-world efficacy and safety of TACE-HAIC combined with TKIs and PD-1 inhibitors in initially unresectable hepatocellular carcinoma.
    Pang B, Zuo B, Huang L, You X, Liu T, Hao J, Yuan C, Yang C, Yee Lau W, Zhang Y.
    Int Immunopharmacol; 2024 Aug 20; 137():112492. PubMed ID: 38906005
    [Abstract] [Full Text] [Related]

  • 13. Clinical efficacy of lenvatinib, trans-arterial chemoembolization, and PD-1/L1 inhibitors in advanced hepatocellular carcinoma: a systematic review and network meta-analysis.
    Liang Y, Gan L, Zeng D, Lin L, Xiong Z, Liao F, Wang A.
    Clin Transl Oncol; 2024 Oct 20; 26(10):2652-2664. PubMed ID: 38671328
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of drug-eluting bead transarterial chemoembolization (DEB-TACE) combined with tyrosine kinase inhibitors (TKIs) in patients with unresectable hepatocellular carcinoma (uHCC): A systematic review and meta-analysis.
    Ji J, Zhang Z, Hou Z, Qiu G, Mi S, Jin Z, Huang J.
    Clin Res Hepatol Gastroenterol; 2024 Apr 20; 48(4):102313. PubMed ID: 38453011
    [Abstract] [Full Text] [Related]

  • 15. Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibodies with Hepatic Arterial Infusion Chemotherapy or Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma.
    Yu B, Zhang N, Feng Y, Zhang Y, Zhang T, Wang L.
    J Hepatocell Carcinoma; 2023 Apr 20; 10():1735-1748. PubMed ID: 37822726
    [Abstract] [Full Text] [Related]

  • 16. Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: A systematic review and meta-analysis.
    Liu JN, Li JJ, Yan S, Zhang GN, Yi PS.
    Front Oncol; 2023 Apr 20; 13():1074793. PubMed ID: 36910612
    [Abstract] [Full Text] [Related]

  • 17. Clinical efficacy of HAIC (FOLFOX) combined with lenvatinib plus PD-1 inhibitors vs. TACE combined with lenvatinib plus PD-1 inhibitors in the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombus and arterioportal fistulas.
    Lin Z, Chen D, Hu X, Huang D, Chen Y, Zhang J, Li X, Zou X.
    Am J Cancer Res; 2023 Apr 20; 13(11):5455-5465. PubMed ID: 38058801
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of hepatic artery infusion chemotherapy combined with tyrosine kinase inhibitors plus programmed death-1 inhibitors for hepatocellular carcinoma refractory to transarterial chemoembolization.
    Lin LW, Ke K, Yan LY, Chen R, Huang JY.
    Front Oncol; 2023 Apr 20; 13():1178428. PubMed ID: 37207144
    [Abstract] [Full Text] [Related]

  • 19. Hepatic arterial infusion chemotherapy versus transarterial chemoembolization for patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
    Kong SY, Song JJ, Jin YQ, Deng MJ, Yan JX.
    Acta Clin Belg; 2023 Apr 20; 78(2):171-179. PubMed ID: 35587164
    [Abstract] [Full Text] [Related]

  • 20. Role of Transarterial Chemoembolization in the Era of Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor Combination Therapy for Unresectable Hepatocellular Carcinoma: A Retrospective Propensity Score Matched Analysis.
    Zhang JX, Hua HJ, Cheng Y, Liu S, Shi HB, Zu QQ.
    Acad Radiol; 2024 Apr 20; 31(4):1304-1311. PubMed ID: 37775449
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.